Pancreatic Cancer Research

ResearcherKing's College Hospital NHS Foundation TrustActive in the last 2 years

Krishna V Menon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8193-4889; OpenAlex author ID A5000664757, A5109678962. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 5 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers

Papers 10

  1. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  2. Delayed surgery during the Covid-19 pandemic did not affect long-term outcomes of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2024.102169↗
  3. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  4. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  5. Extraordinary first jejunal arterial variation associated with annular pancreas undergoing pancreaticoduodenectomy for pancreatic cancer: a case report. Co-author DOI 10.1007/s00276-020-02671-9↗
  6. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  7. Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I study. Last author DOI 10.1016/j.ejso.2021.05.024↗
  8. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  9. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  10. Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation. Last author DOI 10.1093/jscr/rjy127↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andreas A. Prachalias · 3 shared papers, 2021–2025 · strength 0.43
  2. Ricky Harminder Bhogal · 2 shared papers, 2021–2025 · strength 0.32
  3. Albasheer Hamadalnile · 1 shared paper, 2025 · strength 0.24
  4. Jiao Li · 1 shared paper, 2025 · strength 0.24
  5. C. Schneider · 1 shared paper, 2025 · strength 0.24
  6. Michail Papoulas · 2 shared papers, 2018–2021 · strength 0.21
  7. Bilal A. Al-Sarireh · 2 shared papers, 2021 · strength 0.17
  8. Yasuhito Iwao · 1 shared paper, 2021 · strength 0.15
  9. Daisuke Ban · 1 shared paper, 2021 · strength 0.15
  10. Minoru Tanabe · 1 shared paper, 2021 · strength 0.15
  11. Shinji Tanaka · 1 shared paper, 2021 · strength 0.15
  12. Paul J. Ross · 1 shared paper, 2021 · strength 0.11
  13. Kaushal Kundalia · 1 shared paper, 2021 · strength 0.11
  14. Debashis Sarker · 1 shared paper, 2021 · strength 0.11
  15. Yoh Zen · 1 shared paper, 2021 · strength 0.11
  16. Alberto Balduzzi · 1 shared paper, 2021 · strength 0.08
  17. Tobias Keck · 1 shared paper, 2021 · strength 0.08
  18. Riccardo Casadei · 1 shared paper, 2021 · strength 0.08
  19. Andrea Pietrabissa · 1 shared paper, 2021 · strength 0.08
  20. Bergþór Björnsson · 1 shared paper, 2021 · strength 0.08
  21. Adnan A. Alseidi · 1 shared paper, 2021 · strength 0.08
  22. Santiago Sánchez-Cabús · 1 shared paper, 2021 · strength 0.08
  23. Christian Krautz · 1 shared paper, 2021 · strength 0.08
  24. Bjørn Edwin · 1 shared paper, 2021 · strength 0.08
  25. Safi Dokmak · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.